Mankind Pharma Signs Non-Exclusive Patent License Agreement with Takeda to Commercialize Vonoprazan in India
Mumbai, July 16, 2024: Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND) and Takeda Pharmaceutical Company Limited signed a Non-Exclusive Patent License Agreement for commercialising 'Vonoprazan' in the Indian market. The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease (GERD) under its trademark.
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders, including Gastroesophageal Reflux Disease (GERD). The drug is effective in treating conditions such as erosive oesophagitis, gastric ulcer, duodenal ulcer, peptic ulcer, gastro-oesophageal reflux, reflux oesophagitis, and Helicobacter pylori eradication.
Mr. M Ramesh, EVP – Global Business Development - Mankind Pharma Limited, said, “This non-exclusive patent license agreement with Takeda aligns with our commitment to bringing innovative and effective treatments to patients in India. By introducing Vonoprazan, we aim to address a significant medical need and improve the quality of life for those suffering from acid-related illnesses with a new and advanced option for managing acid-related disorders, potentially offering improved health outcomes and quality of life.”
About Mankind Pharma
About Mankind Pharma Mankind Pharma (BSE: 543904 | NSE: MANKIND is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. The company has 30 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 6 dedicated R&D facilities backed by more than 660 scientists.
For more information, visit www.mankindpharma.com or contact:
Corporate Communications Investor Relations
Natasha Raj Abhishek Agarwal
natasha.raj@mankindpharma.com abhishek.agarwal@mankindpharma.com
✍ Share Your Knowledge with Our Community!
get rewards for paying bills
upto ₹250 off when you pay your first bill on CRED